Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Azenta Q2 2026 Earnings Call - Guidance Reset After Multiomics Weakness and Store Quality Headwinds
Azenta reported a disappointing Q2, with organic revenue down 3% and adjusted EBITDA margin compressed to 5.4% as execution gaps and a cautious capital environment in North America hit volumes. Manage...
- Reported Q2 revenue $145 million, up 1% reported, down 3% organically excluding UK Biocentre and FX impact.
- Adjusted EBITDA was $7.8 million, or 5.4% of revenue, down 320 basis points year-over-year.
- Management said they are not satisfied with results, citing execution shortcomings that were within their control and a cautious, prolonged demand environment in North America.
- +13 more takeaways
Limbach Holdings Q1 2026 Earnings Call - Strong Bookings and Data Center Momentum, Near-Term Margin Drag from Pioneer
Limbach reported Q1 2026 revenue of $138.9 million, broadly in line with prior guidance, even as organic revenue declined due to a soft middle of 2025 bookings cadence and normal seasonality. The quar...
- Total Q1 2026 revenue $138.9 million, up 4.3% year-over-year, but total organic revenue down 13.4% as expected due to weaker bookings mid-2025 and seasonal industrial patterns.
- Q1 bookings were $209 million, producing a 1.5 book-to-bill; combined with Q4 2025, the last two quarters yielded over $434 million in bookings, evidence of accelerating demand.
- About 27% of Q1 bookings came from data center opportunities, underscoring management’s push into hyperscaler and mission-critical verticals and faster-converting fabrication-style projects.
- +12 more takeaways
Spire Inc. Q2 2026 Earnings Call - Portfolio Clean Up Funds Tennessee Buy, Weather Shock Creates Near-Term Margin Shortfall
Spire used a fast, surgical set of transactions to fund and close the Piedmont Tennessee acquisition, moving the company to a simpler, fully regulated utility footprint without issuing equity. Managem...
- Spire reported Q2 adjusted continuing operations EPS of $3.76, up from $3.17 a year ago, with adjusted earnings of $224 million for the quarter.
- Management closed the Piedmont Tennessee acquisition on March 31, adding over 200,000 customers in the fast-growing Nashville region, and completed integration planning including an 18-month transition services agreement.
- The Tennessee purchase was funded without issuing common equity, using a financing mix that includes $900 million of junior subordinated notes, $825 million of Spire Tennessee senior notes, proceeds from recent asset sales, and an $800 million term loan bridge until those proceeds arrive.
- +16 more takeaways
International General Insurance Holdings Ltd First Quarter 2026 Earnings Call - Strong Q1 Execution Despite Middle East Losses, Political Violence Seen as Pricing Opportunity
IGI reported a resilient start to 2026, delivering underwriting income of $37.7 million and a combined ratio of 89.1% despite sizeable losses tied to the Middle East conflict. Management emphasized di...
- Gross written premium was $197.2 million, down 4.5% year over year, reflecting deliberate cycle management and two non-renewed reinsurance programs.
- Underwriting income jumped 35.1% to $37.7 million, producing a first quarter combined ratio of 89.1%, 5.3 points better than Q1 2025 and in line with long-term averages.
- The quarter included about $15 million of net losses tied to the Middle East conflict, reflected mainly in the political violence book and an energy loss in the Persian Gulf.
- +14 more takeaways
United Therapeutics Q1 2026 Earnings Call - Ralinepag and TYVASO clinical wins set stage for multi-billion revenue surge
United Therapeutics reported $782 million in Q1 2026 revenue, driven by TYVASO sales of $458 million, while management flagged two clinical readouts that they say change the company’s trajectory. ADVA...
- Q1 2026 revenue was $782 million, with TYVASO sales of $458 million.
- Seasonality, severe winter weather and pharmacy operations issues slowed patient starts in Q1, but management expects sequential growth to resume.
- ADVANCE OUTCOMES top-line results for oral ralinepag showed a threefold reduction in disease progression versus background therapy and durable benefit through four years, per management.
- +13 more takeaways
GXO Q1 2026 Earnings Call - Raises 2026 EBITDA and EPS on Record $2.7B Pipeline and AI/Automation Scale-up
GXO came out of the gates strong in Q1 2026, reporting $3.3 billion in revenue, adjusted EBITDA of $200 million and adjusted EPS of $0.50, each materially ahead year-over-year. Management raised full-...
- Q1 results: Revenue $3.3 billion, up 10.8% year-over-year; adjusted EBITDA $200 million, up 22.7%; adjusted diluted EPS $0.50, up 72.4%.
- Organic revenue growth of 4.1% in Q1, management expects similar growth in Q2 with acceleration in the back half of 2026.
- Guidance raised: full-year adjusted EBITDA to $935 million to $975 million, adjusted diluted EPS to $2.90 to $3.20, representing ~22% EPS growth at the midpoint; organic revenue growth maintained at 4% to 5%.
- +12 more takeaways
Restaurant Brands International Q1 2026 Earnings Call - Burger King Resurgence and International Growth Drive Return to Buybacks
Q1 2026 was a proof point for Restaurant Brands International, with Burger King U.S. and International leading a top-line rebound that translated into outsized organic operating income and double-digi...
- Comparable sales rose 3.2% in Q1 2026, with system-wide sales up 6.2% and net restaurant growth of 2.6%.
- Organic adjusted operating income expanded 10.7% year over year, outpacing system sales growth thanks to OP execution and several one-time tailwinds.
- Adjusted EPS increased 14.6% to $0.86, helped by AOI growth, a small interest expense decline, and an FX tailwind of about $0.04 per share.
- +12 more takeaways
Johnson Controls Q2 2026 Earnings Call - Data Center Demand Sparks 30% Order Jump and $20B Backlog, Lifting Margins
Johnson Controls turned a wave of data center demand into hard results this quarter. Orders jumped 30% and backlog rose 26% to a record $20 billion, helping revenue climb 6% and adjusted EBIT margin e...
- Orders surged 30% in Q2, following nearly 40% growth in the prior quarter, driven largely by large data center projects.
- Backlog grew 26% to a record $20 billion, with management saying roughly 70% of that backlog is convertible to revenue over the next 12 months.
- Organic revenue rose 6% year over year, led by applied HVAC strength and mid-single digit growth in service and systems.
- +16 more takeaways
Taysha Gene Therapies 1Q 2026 Earnings Call - FDA open to 6-month BLA if totality of evidence supports durability
Taysha walked investors through a crisp clinical and CMC sprint aimed at a potential expedited biologics license application for TSHA-102 in Rett syndrome. The company says FDA meetings left the door ...
- FDA meetings: Taysha held a Breakthrough Therapy Type B multidisciplinary meeting and a Type C meeting, and reports constructive FDA dialogue on pivotal design, endpoints, and BLA submission scenarios.
- 6-month BLA option: The FDA signaled the 6-month interim as an option, but approval will depend on the totality of evidence and the agency's comfort with durability—data will decide.
- PPQ campaign started: Taysha initiated its BLA-enabling process performance qualification campaign in April using the commercial TSHA-102 process, with execution expected to complete by Q4 2026.
- +12 more takeaways
Adient Q2 FY2026 Earnings Call - Modest guidance bump as China wins and onshoring offset $35M input-cost shock
Adient delivered a steady quarter: revenue rose 7% year over year to $3.9 billion, helped by FX and underlying volume gains, while adjusted EBITDA slipped to $223 million amid launch costs, temporary ...
- Sales of $3.9 billion in Q2, up 7% year over year, driven by favorable FX and underlying volume gains.
- Adjusted EBITDA was $223 million, down year over year due to launch costs, customer-driven production inefficiencies, and mix shifts.
- Adjusted net income was $41 million, or $0.52 per share.
- +12 more takeaways